Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||APG-2575 + HQP1351|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|APG-2575||APG 2575|APG2575|Lisaftoclax||BCL2 inhibitor 26||APG-2575 is a small molecule that inhibits BCL-2, potentially resulting in increased apoptosis and enhanced antitumor activity in combination with other agents (Cancer Res July 1 2019 (79) (13 Supplement) 2058, PMID: 32093809).|
|HQP1351||HQP 1351|HQP-1351|GZD824 dimesylate|GZD824|Olverembatinib||ABL1 Inhibitor 7 FGFR1 Inhibitor 27 FLT3 Inhibitor 62 KIT Inhibitor 56 PDGFR-alpha Inhibitor 10||GZD824 (HQP1351) is a third-generation BCR-ABL inhibitor and multikinase inhibitor that inhibits KIT, ABL1, FGFR1, FLT3, and PDGFRA (PMID: 32247263), which potentially induces apoptosis, and inhibits tumor cell growth, migration, and invasion (PMID: 31673329).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins||acute myeloid leukemia||predicted - sensitive||APG-2575 + HQP1351||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, combination treatment with GZD824 (HQP1351) and APG-2575 induced apoptosis to a greater degree than either therapy alone in acute myeloid leukemia cells harboring FLT3-ITD in culture, and resulted in a synergistic tumor burden reduction in a patient-derived xenograft (PDX) model of acute myeloid leukemia harboring FLT3-ITD and inhibited tumor growth in a cell line xenograft model with a T/C ratio of 2.8% (PMID: 34710737).||34710737|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|